The three patients with breast cancer treated with abiraterone who achieved an objective response or disease stabilization that lasted longer than 6 months had at least a 70% AR expression; however, six nonresponder patients had also an AR expression that exceeded 70%, among whom only one patient had no other molecular alteration (Data Supplement). This evidence concerns the gene AR and breast carcinoma.